Showing 3361-3370 of 6040 results for "".
- AAD: Sixty Percent of Americans Have Gotten Sunburned So Badly Their Clothes Were Uncomfortablehttps://practicaldermatology.com/news/aad-sixty-percent-of-americans-have-gotten-sunburned-so-badly-their-clothes-were-uncomfortable/2460396/Most Americans say they have gotten a sunburn and admit it has impacted their day-to-day life, according to a recent AAD survey. Of those who have been sunburned, 60 percent said their sunburns made their clothes uncomfortable; 43 percent said they couldn’t sleep; and 21 percent said they w
- The La Roche-Posay North American Foundation Awards 2016 Grant Winnershttps://practicaldermatology.com/news/the-la-roche-posay-north-american-foundation-awards-2016-grant-winners/2458530/Committed to working alongside dermatologists, La Roche-Posay's North American Fondation encourages residents, fellows and practitioners with at least two years beyond training to develop innovative programs. The brand and a board of certified dermatologists awards two to three w
- Dermatology Around the Globe: First JAK for AD Approved in Indiahttps://practicaldermatology.com/news/dermatology-around-the-globe-first-jak-for-ad-approved-in-india/2461828/Intas Pharmaceuticals Ltd launched TOFATAS –a Drugs Controller General of India (DCGI) -approved, Tofacitinib Ointment 2% w/w for the treatment of mild to moderate Atopic Dermatitis (AD) in patients 18 years and above experiencing flare-ups of the disease. "The
- MC2 Therapeutics Reports Positive Topline Data for Investigational Topical for Psoriasishttps://practicaldermatology.com/news/mc2-therapeutics-reports-positive-topline-data-for-investigational-topical-for-psoriasis/2457641/MC2-01 Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) from MC2 Therapeutics A/S achieved its primary and secondary endpoints, according to recently reported top-line data from the US Phase 3 study. Results of the
- SK Breakthrough: FDA Approves Eskata (hydrogen peroxide) Topical Solution from Aclarishttps://practicaldermatology.com/news/sk-breakthrough-fda-approves-eskata-hydrogen-peroxide-topical-solution-from-aclaris/2457950/The FDA has approved ESKATA™ (hydrogen peroxide) topical solution, 40% (w/w) from Aclaris Therapeutics, Inc. for the treatment of seborrheic keratoses (SKs). SKs are non-cancerous skin growths that affect more than 83 million American adults. They may frequently appear in highly visible are
- Study: 60% Lesion Clearance in Actinic Keratosis Patients Using Topical Bimiralisib Gelhttps://practicaldermatology.com/news/study-60-lesion-clearance-in-actinic-keratosis-patients-using-topical-bimiralisib-gel/2471542/Newly presented interim results from a phase 2 clinical trial evaluating bimiralisib topical gel (2%) saw more than half of patients with actinic keratosis achieving complete or partial lesion clearance. Bimiralisib, a pan-PI3
- Topical Gel Bimiralisib Shows Promise for AK in Interim Resultshttps://practicaldermatology.com/news/Topical-Gel-Bimiralisib-Shows-Promise-AK-Interim-Results/2471537/Interim results from an ongoing Phase 2 clinical trial in actinic keratosis highlighted strong potential for the safety and efficacy of topical gel bimiralisib, a selective pan-PI3K/mTOR inhibitor, Torqur AG announced at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Fl
- Delgocitinib Clinical Trials Data Publishedhttps://practicaldermatology.com/news/delgocitinib-clinical-trials-data-published/2467444/LEO Pharma A/S announced that the findings of the DELTA 1 and DELTA 2 phase 3 clinical trials for delgocitinib cream have been published in the peer-reviewed periodical The Lancet. This is the first time The Lancet has published data on an investigational topical pan-Janus kinase (JAK) inhibitor
- Vyne Therapeutics Doses First Patient in Phase 2b Vitiligo Trial of Novel BET Inhibitorhttps://practicaldermatology.com/news/vyne-therapeutics-doses-first-patient-phase-2b-vitiligo-trial-novel-bet-inhibitor/2467132/Vyne Therapeutics announced that the first subject has been dosed in a phase 2b trial evaluating VYN201 in subjects with either active or stable nonsegmental vitiligo. VYN201 is a novel pan-bromodomain and extra-terminal domain (BET) inhibitor designed for local administration. Topline data from
- EMA Accepts LEO Pharma’s MAA for Delgocitinib Cream in Chronic Hand Eczemahttps://practicaldermatology.com/news/ema-accepts-leo-pharmas-maa-for-delgocitinib-cream-in-chronic-hand-eczema/2461942/The European Medicines Agency (EMA) has validated LEO Pharma’s marketing authorization application for delgocitinib cream, an investigational product and topical pan-Janus kinase (JAK) inhibitor for the treatment of adult patients with moderate to severe chronic hand eczema (CHE).